Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial

被引：9

作者：

Escudier, B. J.

Negrier, S.

Gravis, G.

Chevreau, C.

Delva, R.

Bay, J.

Geoffrois, L.

Lagouffe, E.

Blanc, E.

Ferlay, C.

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Ctr Leon Berard, Serv Cancerol Med, F-69373 Lyon, France

[3] Inst J Paoli I Calmettes, INSERM, Dept Med Oncol, UMR 891, F-13009 Marseille, France

[4] Inst Claudius Regaud, Toulouse, France

[5] GINECO, Angers, France

[6] Ctr Jean Perrin, Clermont Ferrand, France

[7] CHU Clermont Ferrand, Clermont Ferrand, France

[8] Ctr Alexis Vautrin, Dept Med Oncol, Nancy, Belgium

[9] Clin Vaidegour, Nimes, France

[10] Ctr Leon Berard, F-69373 Lyon, France

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.4516

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4516

引用

页数：1